Posting of Annual Report and Notice of AGM, Destiny Pharma PLC, 2020-05-12

RNS Number : 6775M
Destiny Pharma PLC
12 May 2020

Destiny Pharma plc

(“Destiny Pharma” or “the Company”)


Posting of Annual Report and Accounts, and Notice of AGM


Brighton, United Kingdom – 12 May 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), announces that the following documents are now available on the Company’s website at


·      Annual Report and Accounts of the Company for the year ended 31 December 2019


·      Notice of the 2020 Annual General Meeting (“AGM) which is to be held at 10.30am on 10 June, 2020


Printed copies of both documents will be posted to shareholders today.


To comply with the UK Government’s Stay at Home measures, shareholders will not be allowed to attend the meeting in person. Shareholders are strongly encouraged to therefore submit their votes, in respect of all matters of business, via proxy as early as possible. They should appoint the Chairman of the meeting as their proxy. If the situation changes then shareholders will be notified via the Company’s website at and via RNS announcement.


For further information, please contact:


Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[email protected] 

+44 (0)1273 704 440


FTI Consulting

Simon Conway / Victoria Foster Mitchell

[email protected] 

+44 (0) 20 3727 1000


finnCap Ltd (Joint Broker)

Geoff Nash / Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

+44 (0)20 7220 0500


WG Partners (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

+44 (0) 203 705 9330


About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel, cost effective medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as “superbugs”. Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit




Leave a Reply

Your email address will not be published.